Business Context and Reporting Period
The filing is an unaudited Form 10-Q for Gemphire Therapeutics Inc. (formerly Michigan Life Therapeutics, LLC), although the request metadata identifies Metavia Inc. The reporting period ended June 30, 2016, covering the three and six months ended that date. Gemphire was a clinical-stage biopharmaceutical company developing gemcabene, an oral treatment candidate for dyslipidemia. It had no approved products and no revenue.
The company reported one operating segment and had nine full-time employees as of June 30, 2016. Its common stock underwent a 1-for-3.119 reverse split effective April 27, 2016; historical share and per-share data were retroactively adjusted.
Financial Performance and Position
| Metric | Three Months Ended June 30, 2016 | Three Months Ended June 30, 2015 | Six Months Ended June 30, 2016 | Six Months Ended June 30, 2015 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| General and administrative expense | $1.1 million | $0.7 million | $2.1 million | $1.1 million |
| Research and development expense | $0.8 million | $1.0 million | $2.0 million | $1.2 million |
| Total operating expenses | $1.8 million | $1.6 million | $4.1 million | $3.2 million |
| Net loss | $1.4 million | $1.6 million | $3.5 million | $3.9 million |
| Net loss attributable to common stockholders | $1.5 million | $1.8 million | $3.8 million | $6.6 million |
| Basic and diluted loss per share | $0.42 loss | $0.60 loss | $1.07 loss | $2.59 loss |
| Net cash used in operating activities | Not separately provided | Not separately provided | $3.8 million | $1.6 million |
As of June 30, 2016, cash and cash equivalents were $4.8 million, compared with $3.6 million at December 31, 2015. Total assets were $6.7 million, total liabilities were $14.4 million, Series A preferred stock had an $8.3 million liquidation preference, and stockholders’ deficit was $16.0 million. The accumulated deficit was $16.0 million.
Cash provided by financing activities was $5.0 million for the six months ended June 30, 2016, primarily from convertible note issuances. Cash increased by $1.2 million during the period. There were no investing cash flows. Operating cash use increased substantially from the prior comparable period.
Outstanding current liabilities included $6.8 million of convertible notes, $4.3 million of convertible notes to related parties, $2.5 million of accrued liabilities, and a $0.2 million premium conversion derivative. The company reported approximately $11.1 million of convertible notes in its contractual-obligations table, including accrued amounts.
Material Changes Versus the Prior Comparable Period
- First-half 2016 total operating expenses increased $0.9 million, or approximately 27%, to $4.1 million.
- General and administrative expense increased $1.0 million, primarily because of higher staffing and professional-services costs.
- Research and development expense increased $0.8 million, reflecting preclinical studies, manufacturing activities, and external clinical-development and regulatory consulting costs.
- The prior-year $0.9 million acquired in-process research and development charge related to an equity milestone payment to Pfizer did not recur.
- Net loss improved by $0.4 million for the first six months, primarily because the prior-year Pfizer charge did not recur and 2016 included favorable non-cash changes related to the convertible-note premium conversion derivative.
- Operating cash use increased from $1.6 million to $3.8 million, despite the lower reported net loss, partly because 2015 included significant non-cash expenses.
- Convertible note financing increased materially, including $5.2 million of 2016 proceeds from February and April issuances. The April financing increased the aggregate Interim Notes principal to approximately $10.6 million.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
Management expected to initiate three late-stage gemcabene clinical trials within the following twelve months, targeting HoFH, hypercholesterolemia including HeFH and ASCVD patients on maximally tolerated statins, and severe hypertriglyceridemia. The company intended to seek an FDA End-of-Phase 2 meeting after one or more trials and pursue related discussions with Canadian and European regulators.
Management expected operating expenses to increase substantially as clinical development advances, regulatory activities expand, manufacturing is arranged, personnel are added, commercialization capabilities are developed, and public-company compliance costs are incurred. The filing did not provide earnings or revenue guidance.
Gemphire had incurred recurring losses since inception, had no committed external funding source, and stated that additional capital would be required. Without adequate financing, it might delay, reduce, or terminate development programs. The filing referenced substantial doubt about going-concern status in the prior-year audit report. Management stated that IPO proceeds and cash on hand were expected to fund operations to mid-2018, but additional capital would still be needed for further development and operations.
Gemcabene was subject to a partial clinical hold restricting trials longer than six months until two-year rat and mouse carcinogenicity studies were completed. Management expected those studies to be completed by the end of 2017. The outcome could affect the timing of long-term trials, regulatory review, labeling, and approval prospects.
The Pfizer license required potential milestone payments of up to $37 million and tiered royalties ranging from the high single digits to low teens on future net sales. No related liability was recorded because the timing and outcome of clinical trials and future sales were uncertain. Pfizer could revoke the license if the company could not adequately commercialize gemcabene by April 2021.
Series A preferred stock accrued 8% cumulative dividends; unpaid dividends totaled approximately $0.5 million at June 30, 2016 and were not recorded because payment was contingent. The preferred stock, convertible notes, and accrued interest converted into common stock in connection with the subsequent IPO.
Subsequent to quarter-end, Gemphire completed an IPO of 3,000,000 shares at $10.00 per share on August 10, 2016 and sold an additional 27,755 shares through a partial over-allotment exercise on September 8, 2016. Net proceeds were approximately $26.0 million. The Series A preferred stock converted into 827,205 common shares, and the convertible notes converted into 1,656,807 common shares immediately before the IPO closing.
Key risks included clinical-trial failure or delay, regulatory rejection, the partial clinical hold, dependence on a single product candidate and Pfizer-licensed intellectual property, reliance on third-party manufacturers and clinical research organizations, competition from established lipid-lowering therapies, future financing needs and dilution, and inability to achieve profitability.
Management stated that disclosure controls and procedures were effective as of June 30, 2016, with no material changes in internal control over financial reporting during the quarter. The filing reported no material legal proceedings and no off-balance-sheet arrangements.
Important Facts for Investors to Verify
- Confirm the issuer identity: the provided filing is for Gemphire Therapeutics Inc., not Metavia Inc.
- Verify the subsequent IPO proceeds, conversion of approximately $10.6 million of convertible notes, and post-IPO capitalization.
- Assess whether the approximately $26.0 million of net IPO proceeds adequately funded the stated clinical-development plan and whether additional financing was subsequently required.
- Review the status and results of the two-year carcinogenicity studies and the FDA partial clinical hold.
- Evaluate clinical-trial initiation, enrollment, safety, efficacy, and regulatory milestones for gemcabene.
- Review the terms, accrued interest, related-party participation, conversion mechanics, and dilution associated with the convertible notes.
- Assess the enforceability and remaining economic value of the Pfizer license, including milestone, royalty, and commercialization obligations.
- Reconcile the contractual-obligation schedule with the balance-sheet presentation of convertible notes and related-party debt.